Medeor Therapeutics, Inc.

12 articles about Medeor Therapeutics, Inc.

• Medeor Therapeutics Announces Interim Data from Pivotal Trial Showing Cell Therapy Technology Could Eliminate Life-Long Need for Immunosuppressant Drugs Following Kidney Transplant

  11/2/2023

  Medeor Therapeutics announced positive interim data from its multicenter, international Phase III clinical trial.

• Medeor Therapeutics to Present Interim Pivotal Data on MDR-101 Cell Therapy for Induction of Immune Tolerance and Elimination of Immunosuppressants Following Kidney Transplant in Late Breaker Oral Presentation at ASN Kidney Week 2023

  10/25/2023

  Medeor Therapeutics announced that it will present interim Phase 3 data investigating if MDR-101 cell therapy can safely induce immune tolerance and eliminate the need for immunosuppressive drugs vs. standard of care following a kidney transplant as a late-breaking oral presentation at the American Society of Nephrology Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.

• Medeor Therapeutics to Provide Interim Results of Phase 3 Mercury Study of MDR-101 Cell Therapy in Living Donor Kidney Transplants During Rapid Fire Oral Presentation at ATC Virtual Congress

  5/20/2021

  Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that interim results of ts Phase 3 study clinical trial for MDR-101 cell therapy

•  Medeor Therapeutics Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy to Establish Tolerance in HLA-Matched Living Donor Kidney Transplants

  5/12/2021

    Medeor Therapeutics Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy to Establish Tolerance in HLA-Matched Living Donor Kidney Transplants

• Medeor Therapeutics Appoints Dr. Daniel Brennan as Chief Medical Officer

  10/14/2020

  Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced the appointment of Daniel Brennan, MD, as Chief Medical Officer. In his role, Dr. Brennan will oversee the clinical development program fo

• Medeor Therapeutics Announces Data Presentation at the American Society of Nephrology Kidney Week 2020

  9/30/2020

  Medeor Therapeutics, Inc. announced that interim results from the company’s MERCURY Phase 3 clinical trial will be presented by lead Principal Investigator Dr. Dixon Kaufman of the University of Wisconsin at the American Society of Nephrology Kidney Week 2020, being held virtually from October 19-25, 2020.

• Medeor Therapeutics’ Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Designation from FDA

  9/22/2020

  Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that the U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101, Medeor’s therapy designed to enable immune tolerance in kidney transplant patients, thereby eliminating the need for

• Medeor Therapeutics Appoints Dr. Karen Smith as President and Chief Executive Officer

  5/28/2019

  Medeor Therapeutics, Inc. announced the appointment of Dr. Karen Smith MD., PhD., as its President and Chief Executive Officer.

• TrakCel to develop and supply Medeor Therapeutics with cellular supply chain management and orchestration system

  9/11/2018

  TrakCel, the cell and gene therapy supply chain tracking and orchestration system software developer, today announces it has been engaged to build a custom-configured system for Medeor Therapeutics.

• Medeor Therapeutics Expands Executive Team

  4/4/2018

  Appointed Iqbal Husain, Ph.D., as its Senior Vice President, Program Management, and Michael Zdanowski as its Vice President, Biopharmaceutical Operations.

• Medeor Therapeutics Awarded $18.8M From the California Institute for Regenerative Medicine

  1/22/2018

  The award is to support a Phase 3 clinical trial to evaluate the safety and efficacy of MDR-101.

• Medeor Receives FDA Clearance Of IND Application And Special Protocol Assessment For Pivotal Clinical Study Of MDR-101

  4/28/2017